Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xioroni plus PD-1 antibody with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
CTR20260141Phase 3Active
- Sponsor
- Chipscreen Biosciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of chiauranib in pancreatic adenocarcinoma (PDAC), sponsored by Chipscreen Biosciences. Started Mar 2026; status: active.
02
Drugs
chiauranib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20260141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260141.